Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861
J Clin Rheumatol. 2021;27(8):e482–e490
Ann Rheum Dis. 2021. Epub ahead of print. doi: 10.1136/annrheumdis-2021-220822.
Drug Saf. 2021 Feb 2. DOI: 10.1007/s40264-020-01036-w
Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.
Arthritis Rheumatol 2019 DOI: 10.1002/art.41032
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215764
Please click the links below to go to the CSF review of each paper.
Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5
Arthritis & Rheumatology. 2015 Jul 2. doi: 10.1002/art.39249. [Epub ahead of print]